[Featured Stock] Suzentec Hits Upper Limit After Obtaining US FDA Emergency Use Authorization for COVID-19 Diagnostic Kit
[Asia Economy Reporter Geum Bo-ryeong] SuzenTech recorded the upper price limit on the 7th following the news that it obtained Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COVID-19 rapid diagnostic kit.
As of 10:30 AM that day, SuzenTech's stock price rose 29.83% (12,500 KRW) from the previous session to 54,400 KRW.
Hot Picks Today
!["Even If I Lose My Investment, the Government Will Cover It"... The Fund Attracting Retail Investors' Attention [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051609052165501_1778889921.jpg)
"Even If I Lose My Investment, the Government Will Cover It"... The Fund Attracting Retail Investors' Attention [Weekend Money]
- Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- AI Said to Eliminate Jobs, but This Role Sees 800% Surge in Hiring [Tech Talk]
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
SuzenTech announced on the same day that it had received EUA from the U.S. FDA for its COVID-19 rapid diagnostic kit. With this approval, SuzenTech is now able to enter the U.S. market.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
